Mabion S.A. (WSE:MAB)

Poland flag Poland · Delayed Price · Currency is PLN
9.57
-0.06 (-0.62%)
Jul 25, 2025, 5:00 PM CET
-0.62%
Market Cap154.67M
Revenue (ttm)37.76M
Net Income (ttm)-39.13M
Shares Out16.16M
EPS (ttm)-2.42
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume53,575
Average Volume24,783
Open9.63
Previous Close9.63
Day's Range9.57 - 9.81
52-Week Range8.38 - 20.45
Beta0.19
RSI42.29
Earnings DateSep 12, 2025

About Mabion

Mabion S.A., a biotechnology company, provides services for the contract development and manufacturing of biologic medicines in Poland. The company offers clinical and commercial drug substance manufacturing of therapeutic proteins using mammalian and insect cell cultures, including biosimilars, monoclonals, other therapeutic proteins, recombinant vaccine antigens, and other recombinant proteins. Its products include MabionCD20 and other products. Mabion S.A. was founded in 2007 and is headquartered in Konstantynów Lódzki, Poland. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2007
Employees 213
Stock Exchange Warsaw Stock Exchange
Ticker Symbol MAB
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.